Ticagrelor monotherapy cuts bleeding risk in acute coronary syndrome

Remedy with ticagrelor alone leads to a decrease price of clinically related bleeding in contrast with ticagrelor and aspirin amongst sufferers with an acute coronary syndrome who had percutaneous coronary intervention and remained event-free for one month on twin antiplatelet remedy, based on a research revealed on-line April 7 in The Lancet to coincide with the annual assembly of the American School of Cardiology, held from April 6 to eight in Atlanta.

Zhen Ge, M.D., from Nanjing First Hospital in China, and colleagues carried out a randomized, double-blind trial involving adults with an acute coronary syndrome with percutaneous coronary intervention with stent placement, who had no main ischemic or bleeding occasions after one-month therapy with twin antiplatelet remedy. Members have been randomly assigned to obtain oral ticagrelor plus oral aspirin or oral ticagrelor plus an identical oral placebo (1,700 sufferers in every group) starting one month after and ending 12 months after percutaneous coronary intervention.

The researchers discovered that clinically related bleeding occurred in 2.1 and 4.6 % of sufferers within the ticagrelor plus placebo group and the ticagrelor plus aspirin group, respectively (hazard ratio, 0.45). Main hostile cardiovascular or cerebrovascular occasions (MACCE) occurred in 3.6 and three.7 % of sufferers within the ticagrelor plus placebo and ticagrelor plus aspirin teams, respectively.

“The current outcomes present that, in these sufferers, therapy with a ticagrelor monotherapy routine between month one and month 12 after the intervention decreases the danger of clinically related bleeding occasions whereas offering related safety from MACCE as in contrast with ticagrelor plus aspirin,” the authors write.

A number of authors disclosed ties to the pharmaceutical and medical system industries.

Copyright © 2024 HealthDay. All rights reserved.